Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses

Vaccine

Volumn 31, Issue 15, 2013, Pages 1898-1904

  Powell, Thomas J ^a   Tang, Jie ^a   DeRome, Mary E ^a   Mitchell, Robert A ^c   Jacobs, Andrea ^a   Deng, Yanhong ^b   Palath, Naveen ^a   Cardenas, Edwin ^a   Boyd, James G ^a   Nardin, Elizabeth ^c  

^a Artificial Cell Technologies Inc   (United States)

^b YALE UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Malaria vaccines; Microparticle; Peptide; Sporozoite

Indexed keywords

CALCIUM CARBONATE; EPITOPE; MALARIA VACCINE; NEUTRALIZING ANTIBODY; PLASMODIUM FALCIPARUM SYNTHETIC LBL MICROPARTICLE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; EFFECTOR CELL; FEMALE; HEPATITIS; IMMUNOGENICITY; MOSQUITO; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SPOROZOITE; T CELL DEPLETION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, PROTOZOAN; CULICIDAE; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNITY, CELLULAR; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PARASITES; PEPTIDES; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SPOROZOITES; T-LYMPHOCYTES; VACCINATION; VACCINES, SYNTHETIC;

EID: 84875255682     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.02.027     Document Type: Article

References (54)

1. Targett G.A., Greenwood B.M. Malaria vaccines and their potential role in the elimination of malaria. Malar J 2008, 7(1):S10.
2. Greenwood B.M., Fidock D.A., Kyle D.E., Kappe S.H., Alonso P.L., Collins F.H., et al. Malaria: progress, perils, and prospects for eradication. J Clin Invest 2008, 118(4):1266-1276. Apr.
3. Nardin E.H., Nussenzweig R.S. T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annu Rev Immunol 1993, 11:687-727.
4. Luke T.C., Hoffman S.L. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 2003, 206(21):3803-3808.
5. Roestenberg M., McCall M., Hopman J., Wiersma J., Luty A.J., van Gemert G.J., et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009, 361(July (5)):468-477.
6. Epstein J.E., Tewari K., Lyke K.E., Sim B.K., Billingsley P.F., Laurens M.B., et al. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 2011, 334(October (6055)):475-480.
7. Casares S., Brumeanu T.D., Richie T.L. The RTS,S malaria vaccine. Vaccine 2010, 28(July (31)):4880-4894.
8. Regules J.A., Cummings J.F., Ockenhouse C.F. The RTS,S vaccine candidate for malaria. Expert Rev Vaccines 2011, 10(May (5)):589-599.
9. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365(November (20)):1863-1875.
10. Agnandji S.T., Lell B., Fernandes J.F., Abossolo B.P., Methogo B.G., Kabwende A.L., et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012, 367(December (24)):2284-2295.
11. Powell T.J., Palath N., Derome M.E., Tang J., Jacobs A., Boyd J.G. Synthetic nanoparticle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo. Vaccine 2011, 29(January (3)):558-569.
12. Persson C., Oliveira G.A., Sultan A.A., Bhanot P., Nussenzweig V., Nardin E. Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. J Immunol 2002, 169(December (12)):6681-6685.
13. Kumar K.A., Oliveira G.A., Edelman R., Nardin E., Nussenzweig V. Quantitative Plasmodium sporozoite neutralization assay (TSNA). J Immunol Methods 2004, 292(September (1-2)):157-164.
14. Othoro C., Johnston D., Lee R., Soverow J., Bystryn J.C., Nardin E. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod. Infect Immun 2009, 77(2):739-748. Feb.
15. Blum-Tirouvanziam U., Beghdadi-Rais C., Roggero M.A., Valmori D., Bertholet S., Bron C., et al. Elicitation of specific cytotoxic T cells by immunization with malaria soluble synthetic polypeptides. J Immunol 1994, 153(November (9)):4134-4141.
16. Frevert U., Moreno A., Calvo-Calle J.M., Klotz C., Nardin E. Imaging effector functions of human cytotoxic CD4+ T cells specific for Plasmodium falciparum circumsporozoite protein. Int J Parasitol 2009, 39(January (1)):119-132.
17. Moreno A., Clavijo P., Edelman R., Davis J., Sztein M., Herrington D., et al. Cytotoxic CD4+ T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein. Int Immunol 1991, 3(October (10)):997-1003.
18. Wu Y., Ellis R.D., Shaffer D., Fontes E., Malkin E.M., Mahanty S., et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 2008, 3(7):e2636.
19. Nussenzweig R.S., Nussenzweig V. Development of sporozoite vaccines. Philos Trans R Soc Lond Ser B, Biol Sci 1984, 307(November (1131)):117-128.
20. Nardin E. The past decade in malaria synthetic peptide vaccine clinical trials. Hum Vaccin 2010, 6(January (1)):27-38.
21. Nardin E.H., Herrington D.A., Davis J., Levine M., Stuber D., Takacs B., et al. Conserved repetitive epitope recognized by CD4+ clones from a malaria-immunized volunteer. Science 1989, 246(December (4937)):1603-1606.
22. Calvo-Calle J.M., Hammer J., Sinigaglia F., Clavijo P., Moya-Castro Z.R., Nardin E.H. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. J Immunol 1997, 159(August (3)):1362-1373.
23. Calvo-Calle J.M., Oliveira G.A., Nardin E.H. Human CD4+ T cells induced by synthetic peptide malaria vaccine are comparable to cells elicited by attenuated Plasmodium falciparum sporozoites. J Immunol 2005, 175(December (11)):7575-7585.
24. Nardin E.H., Calvo-Calle J.M., Oliveira G.A., Nussenzweig R.S., Schneider M., Tiercy J.M., et al. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J Immunol 2001, 166(January (1)):481-489.
25. Moreno A., Clavijo P., Edelman R., Davis J., Sztein M., Sinigaglia F., et al. CD4+ T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. J Immunol 1993, 151(July (1)):489-499.
26. Murray C.J., Rosenfeld L.C., Lim S.S., Andrews K.G., Foreman K.J., Haring D., et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012, 379(February (9814)):413-431.
27. World Malaria Report 2012; 2012.
28. Potocnjak P., Yoshida N., Nussenzweig R.S., Nussenzweig V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med 1980, 151(June (6)):1504-1513.
29. Yoshida N., Nussenzweig R.S., Potocnjak P., Nussenzweig V., Aikawa M. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 1980, 207(January (4426)):71-73.
30. Nardin E.H., Nussenzweig V., Nussenzweig R.S., Collins W.E., Harinasuta K.T., Tapchaisri P., et al. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med 1982, 156(July (1)):20-30.
31. Nardin E.H., Calvo-Calle J.M., Oliveira G.A., Clavijo P., Nussenzweig R., Simon R., et al. Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein. Vaccine 1998, 16(April (6)):590-600.
32. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 2004, 173(September (5)):3148-3154.
33. Fifis T., Mottram P., Bogdanoska V., Hanley J., Plebanski M. Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice. Vaccine 2004, 23(November (2)):258-266.
34. Uto T., Wang X., Akagi T., Zenkyu R., Akashi M., Baba M. Improvement of adaptive immunity by antigen-carrying biodegradable nanoparticles. Biochem Biophys Res Commun 2009, 379(February (2)):600-604.
35. Makidon P.E., Bielinska A.U., Nigavekar S.S., Janczak K.W., Knowlton J., Scott A.J., et al. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS ONE 2008, 3(8):e2954.
36. Mottram P.L., Leong D., Crimeen-Irwin B., Gloster S., Xiang S.D., Meanger J., et al. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm 2007, 4(January-February (1)):73-84.
37. Audran R., Peter K., Dannull J., Men Y., Scandella E., Groettrup M., et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 2003, 21(March (11-12)):1250-1255.
38. Solbrig C.M., Saucier-Sawyer J.K., Cody V., Saltzman W.M., Hanlon D.J. Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor cells. Mol Pharm 2007, 4(January-February (1)):47-57.
39. Hamdy S., Elamanchili P., Alshamsan A., Molavi O., Satou T., Samuel J. Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles. J Biomed Mater Res A 2007, 81(June (3)):652-662.
40. Nembrini C., Stano A., Dane K.Y., Ballester M., van der Vlies A.J., Marsland B.J., et al. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci U S A 2011, 108(November (44)):E989-E997.
41. Bershteyn A., Hanson M.C., Crespo M.P., Moon J.J., Li A.V., Suh H., et al. Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. J Control Release 2012, 157(February (3)):354-365.
42. Uto T., Wang X., Sato K., Haraguchi M., Akagi T., Akashi M., et al. Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol 2007, 178(March (5)):2979-2986.
43. Yang Y.W., Hsu P.Y. The effect of poly(D,L-lactide-co-glycolide) microparticles with polyelectrolyte self-assembled multilayer surfaces on the cross-presentation of exogenous antigens. Biomaterials 2008, 29(June (16)):2516-2526.
44. Schodel F., Wirtz R., Peterson D., Hughes J., Warren R., Sadoff J., et al. Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J Exp Med 1994, 180(September (3)):1037-1046.
45. Allsopp C.E., Plebanski M., Gilbert S., Sinden R.E., Harris S., Frankel G., et al. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur J Immunol 1996, 26(August (8)):1951-1959.
46. Gilbert S.C., Plebanski M., Harris S.J., Allsopp C.E., Thomas R., Layton G.T., et al. A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 1997, 15(November (12)):1280-1284.
47. Birkett A., Lyons K., Schmidt A., Boyd D., Oliveira G.A., Siddique A., et al. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect Immun 2002, 70(December (12)):6860-6870.
48. Mata E., Carcaboso A.M., Hernandez R.M., Igartua M., Corradin G., Pedraz J.L. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice. Vaccine 2007, 25(January (5)):877-885.
49. Kaba S.A., Brando C., Guo Q., Mittelholzer C., Raman S., Tropel D., et al. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J Immunol 2009, 183(December (11)):7268-7277.
50. Pusic K., Xu H., Stridiron A., Aguilar Z., Wang A., Hui G. Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies. Vaccine 2011, 29(November (48)):8898-8908.
51. Moon J.J., Suh H., Li A.V., Ockenhouse C.F., Yadava A., Irvine D.J. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci U S A 2012, 109(January (4)):1080-1085.
52. Kwon Y.J., Standley S.M., Goh S.L., Frechet J.M. Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles. J Control Release 2005, 105(July (3)):199-212.
53. Schlosser E., Mueller M., Fischer S., Basta S., Busch D.H., Gander B., et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008, 26(March (13)):1626-1637.
54. Demento S.L., Eisenbarth S.C., Foellmer H.G., Platt C., Caplan M.J., Mark Saltman W., et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 2009, 27(May (23)):3013-3021.